Skip to main content

What are the new drugs used for multiple sclerosis (MS)?

Medically reviewed by Judith Stewart, BPharm. Last updated on Jan 16, 2023.

Official answer


The newest drugs for the treatment of multiple sclerosis include Briumvi, Ponvory, Kesimpta, Bafiertam, Zeposia, Vumerity, Mavenclad, Mayzent, and Ocrevus.

Multiple sclerosis (MS) is a neurological disease that affects the brain and spinal cord. In MS, the body's immune system attacks the protective myelin sheaths that cover nerve fibers, causing areas of scarring called sclerosis.

MS is a lifelong illness. It can follow one of several different patterns:

  • Relapsing-Remitting MS (RRMS). The most common form of multiple sclerosis characterized by temporary periods of relapses and remissions.
  • Secondary-Progressive MS (SPMS). Most people who are diagnosed with RRMS will transition to SPMS at some stage. In SPMS, symptoms worsen more steadily over time, with or without the occurrence of relapses and remissions.
  • Primary-Progressive MS (PPMS). An uncommon form of MS characterized by slowly worsening symptoms from the onset, with no relapses or remissions.
  • Progressive-Relapsing MS (PRMS). A rare form of MS characterized by a steadily worsening disease state from the onset.

Latest FDA Approvals for Multiple Sclerosis

Brand Generic Name Company Approved Type Indications
Briumvi ublituximab-xiiy
TG Therapeutics, Inc. December 28, 2022 CD20-directed cytolytic monoclonal antibody RRMS, SPMS
Ponvory ponesimod
Janssen Pharmaceuticals, Inc. March 18, 2021 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Kesimpta ofatumumab
Novartis August 20, 2020 CD20-directed cytolytic monoclonal antibody RRMS, SPMS
Bafiertam monomethyl fumarate (delayed-release capsules) Banner Life Sciences LLC April 28, 2020 oral fumarate RRMS, SPMS
Zeposia ozanimod (capsules) Bristol-Myers Squibb Company March 25, 2020 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Vumerity diroximel fumarate
(delayed-release capsules)
Biogen October 29, 2019 oral fumarate RRMS, SPMS
Mavenclad cladribine (tablets) EMD Serono, Inc. March 29, 2019 purine antimetabolite RRMS, SPMS
Mayzent siponimod (tablets) Novartis March 26, 2019 sphingosine-1-phosphate receptor modulator RRMS, SPMS
Ocrevus ocrelizumab (injection) Genentech, Inc. March 28, 2017 CD20-directed cytolytic monoclonal antibody RRMS, SPMS, PPMS
Zinbryta (withdrawn from market March 2018) daclizumab (injection) Biogen May 27, 2016 interleukin-2 receptor blocking antibody RRMS
Lemtrada alemtuzumab (injection) Genzyme Corporation November 14, 2014 CD52-directed cytolytic monoclonal antibody RRMS, SPMS
Plegridy peginterferon beta-1a (injection) Biogen August 15, 2014 pegylated interferon beta RRMS, SPMS
Tecfidera dimethyl fumarate (capsules) Biogen March 27, 2013 Nrf2 pathway activator RRMS, SPMS
Aubagio teriflunomide (tablets) Sanofi September 12, 2012 pyrimidine synthesis inhibitor RRMS, SPMS
Gilenya fingolimod (capsules) Novartis September 21, 2010 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Tysabri natalizumab (injection) Biogen November 23, 2004 integrin receptor antagonist RRMS, SPMS

For more information, see Multiple Sclerosis: What's New in MS Treatment Options?

Drugs in Development for Multiple Sclerosis

Brand Name Generic Name Company Development Stage Type Condition
laquinimod Teva Pharmaceuticals Phase 2/3 CNS-active immunomodulator RRMS, PPMS

Related medical questions

Related support groups